Generic Drugs
Agency Alerts
August 29, 2016
FDA Issues Guidance Regarding the Agency’s Refuse to Receive Policy for Certain Abbreviated New Drug Applications
On Wednesday, August 24th FDA released a final guidance document, entitled “Abbreviated New Drug Application Submissions – Refuse to Receive for Lack of Justification of Impurity Limits,” which...
Generic Drugs
Agency Alerts
August 4, 2016
FDA Generic Drug User Fee Rates: Fiscal Year 2017
FDA has announced its 2017 user fee rates related to the Generic Drug User Fee Program, which includes: Abbreviated new drug applications (ANDAs) Prior approval supplements (PASs) to an approved ANDA...
Generic Drugs
Agency Alerts
June 24, 2016
CREATES Act: Bipartisan Bill to Help Generic Drug Makers Obtain Samples Needed for Clinical Trials
On Tuesday, June 14, the “Creating and Restoring Equal Access to Equivalent Samples Act of 2016” (CREATES Act) was introduced by members of the Senate Judiciary Committee. This bipartisan bill...
Generic Drugs
Agency Alerts
March 31, 2016
Everything You Should Know about FDA’s Draft Guidance on Abuse-Deterrent Generic Opioids, Part Two
FDA Touches on Routes of Abuse, Comparative In Vitro Studies, and Various Other Factors to Consider Regarding Abuse-Deterrent Generic Opioids Due to recent increases in the prevalence of opioid abuse...
Generic Drugs
Agency Alerts
March 30, 2016
Everything You Should Know about FDA’s Draft Guidance on Abuse-Deterrent Generic Opioids, Part One
Evaluating the Abuse Deterrence of Generic Opioid Drug Products As we recently reported, the prevalence of opioid abuse and overdose have reached epidemic levels in the U.S. over the past decade. In...
Generic Drugs
Agency Alerts
January 4, 2016
FDA: Major Rule on Generic Drug Labeling Changes to Come in Summer 2016
In November 2013, the FDA introduced a proposed rule entitled, “Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products.” Last month, the Agency announced the...
Generic Drugs
Agency Alerts
December 16, 2015
Woodcock Announces CDER’s 2016 Priorities & Says ANDA Backlog was the Biggest Challenge of GDUFA I
On Monday, December 14th, the director of FDA's Center for Drug Evaluation and Research (CDER), Janet Woodcock, M.D., spoke at the FDA/CMS Summit for Biopharma Executives where she announced the...
Generic Drugs
Agency Alerts
October 8, 2015
Senator: FDA’s Backlog of ANDAs is Causing “Harm” to Consumers
On September 28, 2015, Sen. David Vitter (R-LA) sent a letter to FDA’s Acting Commissioner, Stephen Ostroff, MD, in which he stated various concerns regarding an extensive backlog of Abbreviated New...
Generic Drugs
Agency Alerts
October 7, 2015
Could Pharmaceutical “Product-Hopping” Violate Antitrust Laws? FTC Thinks So…
In the case between Mylan Pharmaceuticals and Warner Chilcott, in which Mylan accused Warner Chilcott of violating antitrust laws by participating in “product hopping”, the FTC has filed an amicus...